

Ready to start planning your care? Call us at [800-525-2225](tel:800-525-2225) to make an appointment.

×



Memorial Sloan Kettering
Cancer Center

[Make an Appointment](#)

[Back](#)

[Tangible Materials Available for Licensing](#)

[Refer a Patient](#)

[Refer a Patient](#)

ABOUT US

[Our mission, vision & core values](#)

[Leadership](#)

[History](#)

[Equality, diversity & inclusion](#)

[Annual report](#)

[Give to MSK](#)

* As reported in the literature and other commercial supplier websites

Description

Clone 104-2 reacts with CD45 (Leukocyte Common Antigen) on leukocytes of mouse strains that express the CD45.2 alloantigen, including A, AKR, BALB/c, CBA/Ca, CBA/J, C3H/He, C57BL, C57BR, C57L, C58, DBA/1, DBA/2, NZB, SWR, and 129. It has been reported not to react with leukocytes from mouse strains expressing the CD45.1 alloantigen.

Source

This antibody was derived in 1981 by injection of thymocytes and splenocytes from B10.S mice into SJL mice. Splenocytes from these SJL mice were fused with NS-1 cells to generate hybridomas.

Inventors

Edward Boyse, MD, formerly of Memorial Sloan Kettering

Fung-Win Shen, PhD

Key References

Shen FW (1981) Monoclonal antibodies to mouse lymphocyte differentiation alloantigens.

Monoclonal Antibodies and T-Cell Hybridomas: Perspectives and Technical Advances.

Hämmerling GJ, Hämmerling U and Kearney JF, editors. Elsevier/North-Holland Biomedical Press, Amsterdam. 25-31 (ISBN: 9780444803511)

Yakura H et al. (1983) On the function of Ly-5 in the regulation of antigen-driven B cell differentiation. Comparison and contrast with Lyb-2. *Journal of Experimental Medicine* 157: 1077-88 (PubMed ID: [6220106](#))

Licensing Information

This hybridoma may be licensed nonexclusively for commercial purposes. Please note that Anti-CD45.1 Mouse Monoclonal Antibody (Clone A-20) is also available for licensing from MSK. For more information, please contact TRMOTDRTM@mskcc.org.

Additional Information

Purified antibody may be available for sale through the Memorial Sloan Kettering Antibody & Bioresource Core Facility. Please email skiabcf@mskcc.org for further information.

Stage of Development

Ready to use

Types

[Research Tools](#) › [Antibodies/Hybridomas](#)

[Communication preferences](#)

[Cookie preferences](#)

[Legal disclaimer](#)

[Accessibility statement](#)

[Privacy policy](#)

[Price transparency](#)

[Public notices](#)

© 2024 Memorial Sloan Kettering Cancer Center